Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High-Dose Doxorubicin and Ifosfamide Followed by Melphalan and Cisplatin for Patients With High-Risk and Recurrent Sarcoma

NCT00002601 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00002601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High-Dose Doxorubicin and Ifosfamide Followed by Melphalan and Cisplatin for Patients With High-Risk and Recurrent Sarcoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
September 30, 1994
Completion date
September 30, 2014
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma